Microangiopathic Hemolytic Anemia and Diffuse Bone Metastasis by Signet Ring Cell Adenocarcinoma

Andrés J. Muñoz Martín, Pilar García Alfonso, María Carmen Riesco Martínez, Virginia Martínez Marín, Yolanda Jerez Gilarranz, Rebeca Mondejar Solís, Miguel Martín Jiménez

Medical Oncology Service, Hospital General Universitario “Gregorio Maranón”, Madrid, Spain..

DOI: 10.4236/jct.2010.12016                

Abstract

Microangiopathic hemolytic anemia (MAHA) is a rare paraneoplastic syndrome and is typically associated with gastric adenocarcinoma. We report a 47-year-old woman who presented with asthenia, lower back pain and bleeding. Twelve years ago the patient underwent total gastrectomy due to gastric adenocarcinoma and achieved complete remission. The patient was diagnosed with MAHA and diffuses bone metastasis of signet ring cell adenocarcinoma of unknown origin and was treated successfully with polichemotherapy based on cisplatin and 5-fluorouracil.x

Keywords

Microangiopathic Haemolytic Anemia, Gastric Cancer, Paraneoplastic Syndrome, Chemotherapy, Signet Ring Cell Adenocarcinoma?

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. C. Brain, J. V. Dacie and D. O. Hourihane, “Microan-giopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis,” British Journal of Haematology,; Vol. 8, 1962, pp. 358-374.
[2]	K. H. Antman, A. T. Skarin, R. J. Mayer, H. K. Har-greaves and G. P. Canellos, “Microangiophatic Haemolytic Anemia and Cancer: A Review,” Medicine, Baltimore, Vol. 58, 1979, pp. 377-384.
[3]	H. T. Arkenau, O. Mussig, T. Buhr; H. H. Jend and R. Porschen, “Microangiopathic Hemolytic Anemia (MAHA) as Paraneoplastic Syndrome in Metastasized Signet Ring Cell Carcinomas: Case Reports and Review of the Lit-erature,” Z Gastroenterol, Vol. 43, 2005, pp. 719-722.
[4]	F. Ozkalemkas, R. Ali, V. Ozkocaman, T. Ozcelik, U. Ozan, H. Ozturk, E. Kurt, T. Evrensel, O. Yerci and A. Tunali, “The Bone Marrow Aspirate and Biopsy in the Diagnosis of Unsuspected Nonhematologic Malignancy: A Clinical Study of 19 Cases,” BMC Cancer, Vol. 5, 2005, p. 144.
[5]	T. Kanou, Y. Nosou, K. Yoshinaka, E. Yanagawa, M. Niimoto, T. Hattori, K. Miura and J. Kuramoto, “Mi-croangiopathic Hemolytic Anemia Associated with Gastric Cancer,” Gan No Rinsho, Vol. 32, 1986, pp. 1029-1034.
[6]	R. Takeuchi, M. Kuto, N. Katayama, N. Kamio, M. Tsuda, T. Nagano, M. Tomeoku, H. Wada, S. Murashima, K. Deguchi, et al., “Carcinomatosis Associated with Mi-croangiopathic Hemolytic Anemia and Disseminated In-travascular Coagulation: 12 Years after Gastrectomy for Gastric Adenocarcinoma,” Rinsho Ketsueki, Vol. 24, 1983, pp. 1423-1429.
[7]	I. Mizuno, O. Izeki, S. Nakahara, K. Kawamoto, T. Onga, H. Matsuoka, T. Sugimoto, T. Matsui, H. Itoh, K. Chihara, “Disseminated carcinomatosis of the bone marrow occur-ring 11 years after subtotal gastrectomy for gastric cancer,” Rinsho Ketsueki, Vol. 39, 1998, pp. 670-675.
[8]	E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin, A. Ma-jlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, M. L. Risse, J. A. Ajani, et al., “Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,” Journal of Clinical Oncology, Vol. 24, 2006, pp. 4991-4997.
[9]	S. E. Al-Batran, J. T. Hartmann, S. Probst, H. Schmalenberg, S. Hollerbach, R. Hofheinz, V. Rethwisch, G. Seipelt, N. Homann, G. Wilhelm, G. Schuch, J. Stoehlmacher, H. G. Derigs, S. Hegewisch-Becker, J. Grossmann, C. Pauligk, A. Atmaca, C. Bokemeyer, A. Knuth and E. J?ger, “Arbeitsgemeinschaft Internistische Onkologie. Phase III Trial in Metastatic Gastroesophageal Adeno- carcinoma with Fluorouracil, Leuco-Vorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgeme- inschaft Inter- nistische Onkologie,” Journal of Clinical Oncology, Vol. 26, 2008, pp. 1435-1442.
[10]	D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates and A. R. Norman, “Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer,” New England Journal of Medicine, Vol. 358, 2008, pp. 36-46.
[11]	D. A. Podoloff, “PET/CT and Occult Primary Tumors,” Journal of the National Comprehensive Cancer Network; Vol. 7, 2009, pp. 239-244.
[12]	J. S. Macdonald, S. R. Smalley, J. Benedetti, et al., “Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gas-troesophageal Junction,” New England Journal of Medi-cine, Vol. 345, No. 10, 2001, pp. 725-730.